Investors in the Directed Share Issue are a wide range of Swedish and international investors, including AFA Försäkring, Swedbank Robur, Invus Public Equities LP, Point72 Asset Management, Handelsbanken Fonder and Granite Point Capital.
The net proceeds from the Directed Share Issue are intended to be used to advance the company’s lead drug candidate, CAN04, which includes a broader program with clinical studies in new indications such as triple negative breast cancer. The broadening is based on the recent encouraging results with CAN04 in combination with chemotherapy.
“A broader program with clinical studies in new indications such as triple negative breast cancer.”
It will also be used to advance the development of CAN04 in non-small cell lung cancer and pancreatic cancer including additional preparations towards phase III, and the CAN10 clinical development, planned to start early 2022 and continued activities in the platform project CANxx as well as for general corporate purposes and financial flexibility.
“We are truly excited about the recent positive results in the CAN04 project and the subsequent interest from investors in bringing Cantargia’s pipeline forward. Thereby, we can continue with high speed towards our goal of new treatment alternatives for patients with life threatening diseases,” says Göran Forsberg, CEO of Cantargia. “We would like to thank existing and new investors for this valuable support.”
Photo of Göran Forsberg: Cantargia